228 patents
Page 7 of 12
Utility
Nucleic Acid Vaccines
22 Jul 21
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines (NAVs) comprising polynucleotide molecules encoding one or more antigens.
Giuseppe Ciaramella, Axel Bouchon, Eric Yi-Chun Huang
Filed: 17 Mar 21
Utility
RNA polymerase variants
20 Jul 21
The present disclosure provides, in some aspects, variant RNA polymerases, the use of which increases transcription efficiency while reducing the number of double-stranded RNA contaminates and run-on transcripts produced during an in vitro transcription reaction.
Amy E. Rabideau, Athanasios Dousis, Kanchana Ravichandran, Elissa Hobert
Filed: 18 Oct 19
Utility
Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
20 Jul 21
The disclosure features novel lipids and compositions involving the same.
Kerry E. Benenato, Mark Cornebise, Edward Hennessy, Ellalahewage S. Kumarasinghe
Filed: 18 Sep 20
Utility
Variational Autoencoder for Biological Sequence Generation
15 Jul 21
Techniques for manufacturing a variant of a target protein.
Andrew Giessel, Athanasios Dousis, Iain McFadyen
Filed: 8 Jan 21
Utility
Messenger Ribonucleic Acids for the Production of Intracellular Binding Polypeptides and Methods of Use Thereof
8 Jul 21
The invention features isolated mRNAs encoding at least one intracellular binding domain, including mRNAs comprising one or more modified nucleobase and preferably lacking an encoded scaffold polypeptide, and methods of using the same, for example, for inducing apoptosis and/or treating cancer (e.g., liver cancer or colorectal cancer).
Eric Yi-Chun HUANG, Joshua P. FREDERICK, Kristine MCKINNEY, Christina HENDERSON, Kahlin CHEUNG-ONG, Joseph BOLEN, Stephen Michael KELSEY, Michael MORIN, Sushma GURUMURTHY, Kerry BENENATO, Stephen HOGE, Iain MCFADYEN, Vladimir PRESNYAK
Filed: 20 Jan 17
Utility
Compounds and Compositions for Intracellular Delivery of Agents
1 Jul 21
The disclosure features amino lipids and compositions involving the same.
Kerry E. BENENATO, William BUTCHER
Filed: 14 Jun 18
Utility
Varicella zoster virus (VZV) vaccine
29 Jun 21
Aspects of the disclosure relate to nucleic acid vaccines.
Giuseppe Ciaramella
Filed: 15 Mar 18
Utility
Broad Spectrum Influenza Virus Vaccine
24 Jun 21
The disclosure relates to broad spectrum influenza virus ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccine.
Giuseppe Ciaramella, Eric Yi-Chun Huang, Kerim Babaoglu, Jessica Anne Flynn, Lan Zhang, David Nickle
Filed: 15 Mar 18
Utility
Influenza Vaccine
10 Jun 21
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.
Giuseppe Ciaramella
Filed: 18 Dec 20
Utility
Compositions comprising synthetic polynucleotides encoding CRISPR related proteins and synthetic sgRNAs and methods of use
8 Jun 21
The present invention relates to compositions comprising and methods of using synthetic polynucleotides, e.g., modified mRNA, encoding CRISPR related proteins including dCAS9 and synthetic sgRNAs targeting a gene of interest.
Stephen G. Hoge, Eric Yi-Chun Huang, Tirtha Chakraborty
Filed: 11 Jul 14
Utility
Methods for HPLC Analysis
3 Jun 21
Aspects of the disclosure relate to liquid chromatography (e.g., HPLC) methods which enable high resolution separations of polynucleotides having hydrophobic portions (e.g., polyadenylated nucleic acids, such as mRNA) based upon the hydrophobic character of the molecules (e.g., polyA tail length).
William Issa, Meredith Packer
Filed: 17 Aug 18
Utility
Messenger Rna Comprising Functional Rna Elements
3 Jun 21
The present disclosure provides messenger RNAs (mRNAs) having chemical and/or structural modifications, including RNA elements and/or modified nucleotides, in particular C-rich or CG-rich elements, which provide a desired translational regulatory activity to the mRNA.
David REID, Caroline KÖHRER, Ruchi JAIN, Melissa J. MOORE, Scott DONOVAN, Aaron LARSEN, Vladimir PRESNYAK
Filed: 11 Apr 19
Utility
Assembly and Error Reduction of Synthetic Genes from Oligonucleotides
3 Jun 21
The present invention relates to a rapid, high-fidelity process to support synthesis of genes for in vitro transcription of modified messenger RNA.
Marcus R. DUVALL, Kevin SMITH, Robin HUANG, Andrew GIESSEL
Filed: 19 Mar 19
Utility
Compounds and Compositions for Intracellular Delivery of Agents
3 Jun 21
The disclosure features amino lipids and compositions involving the same.
Kerry E. BENENATO, William BUTCHER
Filed: 12 Aug 20
Utility
Compounds and Compositions for Intracellular Delivery of Therapeutic Agents
27 May 21
The disclosure features novel lipids and compositions involving the same.
Kerry E. BENENATO, Ellalahewage Sathyajith KUMARASINGHE, Mark CORNEBISE
Filed: 23 Sep 20
Utility
Rna Formulations
20 May 21
This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins.
Stephen Hoge, Joseph Schariter, Charles Bowerman, Michael H. Smith, Yan Xia
Filed: 15 Jun 18
Utility
Infectious disease vaccines
18 May 21
Aspects of the disclosure relate to nucleic acid vaccines.
Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tai Zaks, Sunny Himansu
Filed: 21 Jul 16
Utility
Polynucleotides encoding interleukin-12 (IL12) and uses thereof
11 May 21
The present disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human interleukin-12 (IL12), functional fragments thereof, and fusion proteins comprising IL12.
Joshua Frederick, Susannah Hewitt, Ailin Bai, Stephen Hoge, Vladimir Presnyak, Iain McFadyen, Kerry Benenato, Ellalahewage Sathyajith Kumarasinghe
Filed: 7 Apr 20
Utility
Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1
11 May 21
The invention relates to mRNA therapy for the treatment of galactosemia type 1 (Gal-1). mRNAs for use in the invention, when administered in vivo, encode human galactose-1-phosphate uridylyltransferase (GALT), isoforms thereof, functional fragments thereof, and fusion proteins comprising GALT. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GALT expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GALT activity in subjects, namely galactose-1-phosphate (Gal-1-P).
Paolo Martini, Stephen Hoge, Kerry Benenato, Vladimir Presnyak, Iain McFadyen, Ellalahewage Sathyajith Kumarasinghe, Ding An, Staci Sabnis
Filed: 18 May 17
Utility
Methods of using OX40 ligand encoding polynucleotides
11 May 21
The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotide molecules comprising an mRNA encoding an OX40L polypeptide.
Joshua P. Frederick, Ailin Bai
Filed: 16 Aug 19